EffRx Pharmaceuticals Signs Exclusive Licensing and Distribution Agreement with Pyridam Farma for Commercialization of BINOSTO® in Indonesia
Press Release EffRx Pharmaceuticals Signs Exclusive Licensing and Distribution Agreement with Pyridam Farma for Commercialization of BINOSTO® in Indonesia May 7, 2024 EffRx Pharmaceuticals Signs Exclusive Licensing and Distribution Agreement with Pyridam Farma for Commercialization of BINOSTO® in Indonesia Freienbach, May 7th 2024 – EffRx Pharmaceuticals SA, a commercial-stage pharmaceutical company focused on the development […]
EffRx Pharmaceuticals Signs Exclusive Licensing and Distribution Agreement with Lupin for Commercialization of BINOSTO® in Vietnam & Philippines
Freienbach, February 6, 2024 – EffRx Pharmaceuticals SA, a commercial-stage pharmaceutical company focused on the development and commercialization of musculoskeletal and rare diseases medications, today announced
EffRx Pharmaceuticals Signs Exclusive Licensing Agreement With Radius Health To Commercialize BINOSTO® In The United States
Freienbach, September 19th, 2023 – EffRx Pharmaceuticals SA, a commercial-stage pharmaceutical company focused on the development and commercialization of musculoskeletal and rare diseases medications, today announced
Abiogen Pharma Completes the Acquisition of EffRx
Press Release Abiogen Pharma Completes the Acquisition of EffRx May 29, 2023 Abiogen Pharma Completes the Acquisition of EffRx EffRx Pharmaceuticals SA joins forces with Abiogen Pharma S.p.A. Read PR: Abiogen & EffRx Press Release Contact Wolleraustrasse 41B, 8807 Freienbach, Switzerland +41 44 503 78 60 info@effrx.com SHARE THIS ARTICLE
EffRx Pharmaceuticals announces the launch of Alkindi® as replacement therapy for pediatric adrenal insufficiency in Switzerland
Press Release EffRx Pharmaceuticals announces the launch of Alkindi® as replacement therapy for pediatric adrenal insufficiency in Switzerland July 20, 2022 EffRx Pharmaceuticals announces the launch of Alkindi® as replacement therapy for pediatric adrenal insufficiency in Switzerland FREIENBACH, Switzerland – EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, […]
World Orphan Drug Alliance – combining forces to reach patients with rare diseases across the globe
Press Release World Orphan Drug Alliance – combining forces to reach patients with rare diseases across the globe July 20, 2022 World Orphan Drug Alliance – combining forces to reach patients with rare diseases across the globe World Orphan Drug Alliance (WODA) is a new global alliance of full-service regional distributors for orphan drugs. WODA covers […]
EffRx Pharmaceuticals Signs Exclusive License Agreement with Diurnal for the Registration and Commercialization of Efmody® in Switzerland
Press Release EffRx Pharmaceuticals Signs Exclusive License Agreement with Diurnal for the Registration and Commercialization of Efmody® in Switzerland April 26, 2022 EffRx Pharmaceuticals Signs Exclusive License Agreement with Diurnal for the Registration and Commercialization of Efmody® in Switzerland FREIENBACH, Switzerland –-BUSINESS WIRE–- EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in […]
